<DOC>
	<DOCNO>NCT00229645</DOCNO>
	<brief_summary>Major depression occur generalize anxiety disorder panic disorder 60 % psychiatric primary care patient . ( 1 ) An estimate 85 % adults depression experience significant symptom anxiety 58 % diagnosable anxiety disorder lifetime . ( 2 ) Numerous study show symptom anxiety frequent patient major depressive disorder , presence anxiety symptom associate severe chronic course . ( 3,4 ) This comorbidity associate great severity depression , poor psychosocial functioning , poor treatment response high risk suicide . The data suggest novel antipsychotic antidepressant anxiolytic effect . This study explore impact effect patient major depression comorbid anxiety symptom . This study offer possibility systematically review role quetiapine depression anxiety . If combination SSRI SNRI quetiapine prof effective could offer viable alternative widespread benzodiazepine use .</brief_summary>
	<brief_title>A Double Blind , Randomized Placebo Controlled Study Efficacy , Safety Quetiapine Fumarate ( SeroquelÂ® ) Potentiation SSRI 's , SNRI 's Treatment Major Depression With Anxiety</brief_title>
	<detailed_description>This double blind study patient involve treatment period 8 week . The initial evaluation include rating scale measure depression , anxiety , severity illness , overall functioning , pregnancy test clinical evaluation . Patients treat SSRI SNRI least 6 week , therapeutic dos ( see table 1 . ) , still HAM-D score 18 , randomly assign treatment , either Quetiapine , Placebo . Patients active group titrate fixed schedule 50 mg night 7 day , 100 mg night 7 day , 200 mg night 7 day . After dose titrated upwards maximum 600mg night discretion investigator , use patient tolerance response guideline duration trial . 200mg range average dose large trial naturalistic clinical use quetiapine actually much slow titration schedule package label . Patients tolerate 200mg/day withdrawn study . Patients try minimum 400mg /day withdraw lack efficacy . This dose remain steady week 8 . Rating scale repeat every week first 2 week , every 2 week end study week 8 .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>1 . Patients DSM IV diagnosis major depression . 2 . Patients antipsychotic benzodiazepine least 7 day prior enter study . 3 . Patients able give inform consent . 4 . Patients male female age 18 65 . 5 . Subjects treat least 6 week single agent SSRI SNRI therapy acceptable dose ( see table 1 detail ) current episode . 6 . Patients score least 18 17item HAMD scale , score least 14 14item HAMA scale least 4 ( i.e. , moderately ill ) Clinical Global Impression ( CGI ) severity scale . Both criterion meet screen baseline ( Study Day 0 ) . 1 . Patients , investigator 's opinion , pose risk suicide . 2 . Present DSM IV diagnosis substance abuse dependence within 6 month screen visit . 3 . Female subject child bear potential without adequate contraception . Adequate method contraception include hormonal contraceptive e.g . oral contraceptive long term injectable implantable hormonal contraceptive ; double barrier method , example condom diaphragm , condom foam , condom sponge ; intrauterine device tubal ligation . 4 . Pregnant breastfeeding female . 5 . Documented disease central nervous system include limited stroke , tumor , seizure disorder require anticonvulsant , history brain trauma , chronic infection dementing illness . 6 . Hepatic , renal gastrointestinal disease sufficient degree interfere excretion , absorption and/or metabolism trial medication . 7 . Acute , unstable significant untreated medical illness . 8 . Subjects narrow angle glaucoma , chronic urinary retention and/or clinically significant prostatic hypertrophy , paralytic ileus related condition . 9 . A history severe drug allergy hypersensitivity . 10 . The use follow potent cytochrome P450 inhibitor 14 day precede randomization ( e.g . ketoconazole , itraconazole , fluconazole , erythromycin , troleandomycin clarithromycin , indinavir , nelfinavir , ritonavir saquinavir ) . 11 . The use potent cytochrome P450 inducer ( e.g . phenytoin , carbamazepine , barbiturate , rifampin glucocorticoid ) 14 day precede randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Major Depression</keyword>
	<keyword>Anxiety</keyword>
</DOC>